Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Certara Inc (CERT)

Certara Inc (CERT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Tax-Loss Selling Just Created a Major Buying Opportunity in These 2 Tech Stocks

Every December, the stock market creates a powerful pocket of opportunity through a little-noticed force known as tax-loss selling. This practice involves investors selling their losing stocks to offset capital-gains taxes. In 2025, the effect was especially strong after a year filled with U.S. market gains. As a result, the stocks of many fundamentally sound companies were pushed lower — not because their businesses deteriorated, but simply because investors were tidying up their tax books. That selling pressure tends to fade once the calendar flips. 

As 2026 gets underway, these stocks could begin to recover as bargain hunters and long-term investors...

Fundamentals

See More
  • Market Capitalization, $K 1,540,170
  • Shares Outstanding, K 159,273
  • Annual Sales, $ 385,150 K
  • Annual Income, $ -12,050 K
  • EBIT $ 82 M
  • EBITDA $ 151 M
  • 60-Month Beta 1.46
  • Price/Sales 3.75
  • Price/Cash Flow 13.30
  • Price/Book 1.44

Options Overview Details

View History
  • Implied Volatility 220.07% (+54.71%)
  • Historical Volatility 38.62%
  • IV Percentile 88%
  • IV Rank 45.79%
  • IV High 423.10% on 12/10/25
  • IV Low 48.60% on 01/21/25
  • Expected Move (DTE 7) 2.24 (23.12%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 57
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 1,862
  • Open Int (30-Day) 1,716
  • Expected Range 7.43 to 11.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.07
  • Number of Estimates 3
  • High Estimate 0.08
  • Low Estimate 0.06
  • Prior Year 0.12
  • Growth Rate Est. (year over year) -41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.42 +14.90%
on 12/15/25
9.87 -2.03%
on 01/08/26
+0.58 (+6.38%)
since 12/08/25
3-Month
8.02 +20.50%
on 11/20/25
13.12 -26.30%
on 10/09/25
-3.33 (-25.62%)
since 10/08/25
52-Week
8.02 +20.50%
on 11/20/25
15.69 -38.37%
on 02/14/25
-1.35 (-12.25%)
since 01/08/25

Most Recent Stories

More News
Tax-Loss Selling Just Created a Major Buying Opportunity in These 2 Tech Stocks

Tax-loss selling at the end of 2025 knocked these two tech stocks into bargain territory, opening the door for a potential rebound in 2026.

FRSH : 11.74 (-1.59%)
SPGI : 541.56 (+0.76%)
CERT : 9.67 (+1.90%)
BRDCF : 21.7100 (-6.91%)
NUE : 167.88 (+1.86%)
Certara Appoints Jon Resnick as Chief Executive Officer

Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company...

CERT : 9.67 (+1.90%)
AI Spending in Healthcare and Wellness Triples as Personalized Wellness Platforms Scale

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – Healthcare's artificial intelligence transformation is accelerating at unprecedented speed, with AI spending hitting...

OPRX : 13.36 (-3.54%)
CTSH : 85.77 (+1.97%)
CERT : 9.67 (+1.90%)
OABI : 1.8900 (-0.53%)
ALEN-U.CN : 1.3000 (unch)
AI Wellness Market Surges as Personalized Health Platforms Capture Investment Flow

Issued on behalf of Aleen Inc. VANCOUVER – Baystreet.ca News Commentary – AI-powered wellness platforms are commercializing rapidly as major technology companies launch personalized health...

ZBH : 94.08 (+1.52%)
CAI : 28.25 (-1.84%)
CERT : 9.67 (+1.90%)
ACN : 281.82 (+2.86%)
ALEN-U.CN : 1.3000 (unch)
Certara Reports Third Quarter 2025 Financial Results

RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year...

CERT : 9.67 (+1.90%)
Certara Automates Scientific Workflows with Phoenix® Cloud

RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module...

CERT : 9.67 (+1.90%)
Certara to Participate in Upcoming Investor Conferences

RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following...

CERT : 9.67 (+1.90%)
Certara Expands Biosimulation Market with AI-Driven QSP Platform

RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative...

CERT : 9.67 (+1.90%)
Certara Scientists are Among the Topmost Cited Biopharma Researchers

RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With...

CERT : 9.67 (+1.90%)
Morgan Stanley Remains a Hold on Certara (CERT)

In a report released today, Craig Hettenbach from Morgan Stanley maintained a Hold rating on Certara, with a price target of $16.00. The company’s shares closed yesterday at $12.25.Elevate Your Investing...

CERT : 9.67 (+1.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Certara Inc. provides medicines to patients using proprietary biosimulation software and technology to transform traditional drug discovery and development. Certara Inc. is based in NJ, United States.

See More

Key Turning Points

3rd Resistance Point 10.39
2nd Resistance Point 10.13
1st Resistance Point 9.90
Last Price 9.67
1st Support Level 9.41
2nd Support Level 9.15
3rd Support Level 8.92

See More

52-Week High 15.69
Fibonacci 61.8% 12.76
Fibonacci 50% 11.86
Fibonacci 38.2% 10.95
Last Price 9.67
52-Week Low 8.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar